Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00328107 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults
A Phase 2 study, sponsored by Protein Sciences Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 459
- Enrollment target
NCT00328107: Completed Phase 2 study, sponsored by Protein Sciences Corporation.
NCT00328107 is a Phase 2 study that has completed, run by Protein Sciences Corporation. The registered enrollment target is 459 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (245% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00328107, a Phase 2 study, has completed, sponsored by Protein Sciences Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 459 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the dose-related safety, immunogenicity, and protective efficacy of a trivalent recombinant hemagglutinin influenza vaccine in healthy adults.
Interventions
- BIOLOGICAL Influenza Vaccine, recombinant Hemagglutinin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2004-11 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
What the finished NCT00328107 record still lists
NCT00328107 is an interventional study that assigns participants to a tested intervention. The registered 459 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (245% higher).
The record links to 0 conditions, and to 1 intervention - of which Influenza Vaccine, recombinant Hemagglutinin is the first listed.
NCT00328107 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00328107 about?
NCT00328107 is a clinical study titled "Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults". The purpose of this study was to determine the dose-related safety, immunogenicity, and protective efficacy of a trivalent recombinant hemagglutinin influenza vaccine in healthy adults.
What is the current status of trial NCT00328107?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 459 participants. The study started on 2004-11. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00328107?
The interventions under investigation include: Influenza Vaccine, recombinant Hemagglutinin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00328107?
This trial is sponsored by Protein Sciences Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00328107's enrollment target sits among peer trials
459 84th of 2000 higher than 1,917 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04452825 · 459 participants · NA
A New Psychotherapy Intervention for Older Cancer Patients
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia